Home Cart Sign in  
Chemical Structure| 6054-98-4 Chemical Structure| 6054-98-4

Structure of Olsalazine Disodium
CAS No.: 6054-98-4

Chemical Structure| 6054-98-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Olsalazine Sodium is a prodrug of mesalamine with anti-inflammatory activity used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.

Synonyms: Olsalazine Sodium; Olsalazine(sodium salt); C.I. 14130

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Olsalazine Disodium

CAS No. :6054-98-4
Formula : C14H8N2Na2O6
M.W : 346.20
SMILES Code : O=C([O-])C1=CC(/N=N/C2=CC=C(O)C(C([O-])=O)=C2)=CC=C1O.[Na+].[Na+]
Synonyms :
Olsalazine Sodium; Olsalazine(sodium salt); C.I. 14130
MDL No. :MFCD00013300
InChI Key :ZJEFYLVGGFISGT-UHFFFAOYSA-L
Pubchem ID :135413505

Safety of Olsalazine Disodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01320436 Ulcerative Colitis Phase 3 Completed - Israel ... More >> Sheba Medical Center Ramat Gan, Israel Less <<
NCT00004288 Ankylosing Spondylitis Phase 2 Completed - -
NCT03423810 Polycystic Kidney Diseases Early Phase 1 Recruiting May 15, 2019 United States, Kansas ... More >> University of Kansas Medical Center Recruiting Kansas City, Kansas, United States, 66160 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.44mL

2.89mL

1.44mL

28.89mL

5.78mL

2.89mL

References

[1]Brown WA, Farmer KC, et al. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci. 2000 Aug;45(8):1578-84.

[2]Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64.

[3]Niu Y, Li H, Gao L, Lin H, Kung H, Lin MC, Leung KS, Wong MH, Xiong W, Li L. Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity. J Pharmacol Sci. 2017 Nov;135(3):114-120. doi: 10.1016/j.jphs.2017.10.007. Epub 2017 Oct 31. PMID: 29132796.

[4]Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987 Dec;93(6):1255-62. doi: 10.1016/0016-5085(87)90253-8. PMID: 2890550.

[5]Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schütz E, Otto P, Lorenz-Mayer H, Ewe K, Judmaier G. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther. 1998 Aug;12(8):707-15. doi: 10.1046/j.1365-2036.1998.00360.x. PMID: 9726382.

[6]Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64. doi: 10.2165/00003495-199141040-00009. PMID: 1711964.

 

Historical Records

Categories